Skip to content

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.66B+6.2%
Eli Lilly logo
Eli LillyLLY
$26.54B+43.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$23.27B+11.5%
Amgen logo
AmgenAMGN
$8.22B+23.0%
AbbVie logo
AbbVieABBV
$5.69B+8.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$41.62M-15.4%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s PP&E (net)?
Oruka Therapeutics, Inc. (ORKA) reported PP&E (net) of $318K in Q1 2026.
How has Oruka Therapeutics, Inc.'s PP&E (net) changed year-over-year?
Oruka Therapeutics, Inc.'s PP&E (net) increased by 100.0% year-over-year, from $159K to $318K.
What is the long-term trend for Oruka Therapeutics, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s PP&E (net) has grown at a 68.8% compound annual growth rate (CAGR), from $21K to $288K.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.